Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | ARG1 | P05089 | 1/20 | 0.44 |
| ▸ | CTSC | P53634 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL689400 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL5636193 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL1270327 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL7361978 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL7338717 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL7338708 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL1269918 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| Hydrochloric Acid SCHEMBL1302881 | 0.98 | CYP2D6 (0.50) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| Hydrochloric Acid SCHEMBL1268656 | 0.98 | CYP2D6 (0.50) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| Hydrochloric Acid SCHEMBL20446559 | 0.98 | CYP2D6 (0.50) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4703038-A | HYPOTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1987-10-27 | — | — | US | claimed |
| US-4684660-A | Mercaptoacyldepeptides | E. R. SQUIBB & SONS, INC. (US) | 1987-08-04 | — | — | US | claimed |
| EP-0180785-A1 | Pharmaceutical preparation containing a combination of Nitrendipin and Enalapril and process for its preparation | BAYER AG (DE) | 1986-05-14 | — | — | EP | claimed |
| US-4482725-A | ANGIOTENSIN CONVERTING ENZYME INHIBITOR | E. R. SQUIBB & SONS, INC. (US) | 1984-11-13 | — | — | US | claimed |
| US-4472380-A | CARBOXYALKYL DIPEPTIDE DERIVATIVES | MERCK & CO., INC. (US) | 1984-09-18 | — | — | US | claimed |
| US-4325943-A | HYPOTENSIVE AGENTS, DIURETICS | E. R. SQUIBB & SONS, INC. (US) | 1982-04-20 | — | — | US | claimed |
| US-4284624-A | HYPOTENSIVE PEPTIDES | E. R. SQUIBB & SONS, INC. (US) | 1981-08-18 | — | — | US | claimed |
| EP-0012401-A1 | Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1980-06-25 | — | — | EP | claimed |
| CN-119020332-A | Botulinum neurotoxin which cleaves non-neuronal SNARE | 益普生生物制药有限公司 | 2024-11-26 | — | — | CN | disclosed |
| US-12084462-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-10 | — | — | US | disclosed |
| CN-111406066-B | Botulinum neurotoxin which cleaves non-neuronal SNARE | 益普生生物制药有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-117979988-A | Modified BoNT/a for treating diseases affecting eyelid muscles in a subject | 益普生生物制药有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20240082344-A1 | METHOD OF TREATING PRADER-WILLI SYNDROME | FERRING B.V. (NL) | 2024-03-14 | — | — | US | disclosed |
| EP-3666258-B1 | METHOD OF TREATING PRADER-WILLI SYNDROME | FERRING BV (NL) | 2023-11-15 | — | — | EP | disclosed |
| US-4316906-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-02-23 | — | — | US | disclosed |
| US-4284624-A | HYPOTENSIVE PEPTIDES | E. R. SQUIBB & SONS, INC. (US) | 1981-08-18 | — | — | US | disclosed |
| US-4221912-A | Dithio derivatives of 4,5-dihydro-1H-pyrrole-2-carboxylic acids and 1,4,5,6-tetrahydropyridine-2-carboxylic acids | E. R. SQUIBB & SONS, INC. (US) | 1980-09-09 | — | — | US | disclosed |
| US-4217458-A | Acylmercaptoacyl derivatives of 4,5-dihydro-1H-pyrrole-2-carboxylic acids and 1,4,5,6-tetrahydropyridine-2-carboxylic acids | E. R. SQUIBB & SONS, INC. (US) | 1980-08-12 | — | — | US | disclosed |
| EP-0012401-A1 | Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1980-06-25 | — | — | EP | disclosed |
| US-4198515-A | Mercaptoacyl derivatives of 4,5-dihydro-1H-pyrrole-2-carboxylic acids and 1,4,5,6-tetrahydropyridine-2-carboxylic acids | E. R. SQUIBB & SONS, INC. (US) | 1980-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12084462-B2 | Spiro bicyclic inhibitors of menin-MLL interaction | BMI1, MLLT1, MEN1 | CYP2D6 3831/4885CYP1A2 4138/4885ALOX15 3500/4885 |
| US-20240082344-A1 | METHOD OF TREATING PRADER-WILLI SYNDROME | OXTR, MC2R, AVPR2 | CYP2D6 3478/4885CYP1A2 4362/4885ALOX15 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.